Obinutuzumab Controls Growth of Slow-Growing Non-Hodgkin Lymphoma

ASCO Annual Meeting
May 30, 2015

In an ongoing study, researchers found that adding a new targeted therapy to chemotherapy controls non-Hodgkin lymphoma (NHL) growth for more than twice as long as only chemotherapy. The patients who participated in this study had indolent, or slow-growing, NHL. The standard first treatment for this common type of NHL is a combination of bendamustine (Treanda) and rituximab (Rituxan). For most patients, rituximab eventually stops working to control NHL growth.

Targeted Therapy Combination for Lymphoma Is More Effective Than Standard Chemotherapy

ASCO Annual Meeting
June 3, 2012

A long-term study shows that a combination of bendamustine (Treanda) and rituximab (Rituxan) keeps two uncommon types of non-Hodgkin lymphoma (NHL), indolent (slow-growing) lymphoma and mantle cell lymphoma, from worsening longer than standard chemotherapy. Bendamustine and rituximab are drugs called targeted therapies. Targeted therapy is a treatment that targets the cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Preliminary Study Shows that the Lung Cancer Drug, Crizotinib, Is Effective for Three Childhood Cancers

ASCO Annual Meeting
May 16, 2012

In an early study with the targeted therapy drug crizotinib (Xalkori), researchers found that it stopped the growth of neuroblastoma, anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumors (IMT), and in some instances, removed all signs of the cancer.

Subscribe to RSS - Lymphoma